Evidence map›Paper›PMID 26837698›Full record

ArticleBlood2016

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

Saad Sirop Kenderian, Thomas M Habermann, William R Macon, Kay M Ristow, Stephen M Ansell, Joseph P Colgan, Patrick B Johnston, David J Inwards, Svetomir N Markovic, Ivana N Micallef and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Saad Sirop KenderianDivision of Hematology, Department of Internal Medicine.ORCID http://orcid.org/0000-0003-2767-3830
Thomas M HabermannDivision of Hematology, Department of Internal Medicine.
William R MaconDepartment of Laboratory Medicine and Pathology, and.
Kay M RistowDivision of Hematology, Department of Internal Medicine.
Stephen M AnsellDivision of Hematology, Department of Internal Medicine.
Joseph P ColganDivision of Hematology, Department of Internal Medicine.
Patrick B JohnstonDivision of Hematology, Department of Internal Medicine.
David J InwardsDivision of Hematology, Department of Internal Medicine.
Svetomir N MarkovicDivision of Hematology, Department of Internal Medicine.
Ivana N MicallefDivision of Hematology, Department of Internal Medicine.
Carrie A ThompsonDivision of Hematology, Department of Internal Medicine.
Luis F PorrataDivision of Hematology, Department of Internal Medicine.
James A MartensonDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN.
Thomas E WitzigDivision of Hematology, Department of Internal Medicine.
Grzegorz S NowakowskiDivision of Hematology, Department of Internal Medicine.
Emory University Hospital · USMayo Clinic in Arizona · US

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
NCI NIH HHS P50 CA097274
6 · The paper itself

Abstract

A number of reports have shown a propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL). Long-term data on the incidence and outcomes of transformed NLPHL are lacking. A comprehensive analysis of the actively maintained Mayo Clinic Lymphoma Database was performed. Between 1970 and 2011, 222 consecutive adult patients with new untreated NLPHL were identified. Median age at diagnosis was 40 years, and 146 (66%) were males. The median follow-up was 16 years. Seventeen patients (7.6%) developed a transformation to DLBCL. The median time to transformation was 35 months (range, 6-268 months). Based on the observed 17 transformations during 2304 patient-years of follow-up, the rate of transformation was 0.74 per 100 patient-years. In a multivariate analysis, use of any prior chemotherapy ( ITALIC! P= .04) and splenic involvement ( ITALIC! P= .03) were significantly associated with increased risk of transformation. The 5-year overall survival (OS) in those with transformed disease was 76.4%, and transformation did not adversely affect OS when compared with patients who did not experience transformation. In this large single-institution cohort with long-term follow-up, the risk of transformation was lower than that observed in other low-grade lymphomas.

Indexed as

AdolescentAdultAgedAged, 80 and overB-LymphocytesCell Transformation, NeoplasticChildFemaleFollow-Up StudiesHodgkin DiseaseHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedSurvival AnalysisYoung Adult

Identifiers

PMID26837698
PMCPMC4841039
OpenAlexW2253668567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.